BRIEF published on 04/08/2026 at 22:05, 6 months 23 days ago Inventiva Submits 2025 Financial Reports to AMF and SEC Inventiva 2025 Financial Reports MASH Treatments Biopharmaceutical Developments AMF And SEC Filings
PRESS RELEASE published on 04/08/2026 at 22:00, 6 months 23 days ago Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F Inventiva files 2025 Universal Registration Document and Annual Report on Form 20-F with AMF and SEC, focusing on MASH therapies Biopharmaceutical 2025 Filing Inventiva MASH
BRIEF published on 04/02/2026 at 15:55, 6 months 29 days ago JP Morgan Chase & Co. crosses the thresholds for participation in INVENTIVA Voting Rights Threshold Crossing JP Morgan Inventiva Equity Swap
BRIEF published on 03/30/2026 at 22:16, 7 months 2 days ago Inventiva Announces 2025 Financial Results and Business Update Public Offering Cash Reserves Inventiva Lanifibranor 2025 Financial Results
PRESS RELEASE published on 03/30/2026 at 22:11, 7 months 2 days ago Inventiva reports 2025 full year results and provides a business update Inventiva reports 2025 full year results with €4.5 million revenues, provides business update on strategic pipeline, clinical trials, and financial performance Financial Performance Business Update Clinical Trials Inventiva 2025 Results
BRIEF published on 03/23/2026 at 22:05, 7 months 9 days ago Inventiva Announces Schedule for 2025 Financial Results Financial Results Conference Call Biopharmaceutical Inventiva MASH
BRIEF published on 03/23/2026 at 22:05, 7 months 9 days ago Inventiva announces its 2025 annual financial results Financial Results Conference Call Investors Steatohepatitis Oral Therapy
PRESS RELEASE published on 03/23/2026 at 22:00, 7 months 9 days ago Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results Inventiva to release 2025 full-year financial results on March 30, 2026, followed by a conference call on March 31, 2026. Details on the company's website Financial Results Conference Call Biopharmaceutical Inventiva Therapy
BRIEF published on 03/23/2026 at 09:51, 7 months 9 days ago JP Morgan Chase & Co. crosses ownership thresholds in INVENTIVA Actions Participation Threshold Crossing JP Morgan Inventiva
BRIEF published on 03/23/2026 at 09:50, 7 months 9 days ago Threshold crossings at INVENTIVA Shareholders Voting Rights Inventiva Threshold Crossings Shareholders' Agreement
Published on 10/30/2026 at 23:35, 2 days 6 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 2 days 6 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 2 days 11 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 14 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/01/2026 at 10:35, 19 hours 31 minutes ago Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 1 day 1 hour ago 2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 1 day 13 hours ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 2 days 7 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 2 days 7 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 18:00, 2 days 12 hours ago 2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 2 days 18 hours ago Capital increase through exercise of subscription rights
